Yubo International Biotech Limited (YBGJ) Stock Price & Analysis
Yubo International Biotech Limited (YBGJ) — price $0.0055 (0.00%), as of the Nov 19, 2026 trading session.
Educational signal · not a buy or sell recommendation · How to read this
Yubo International Biotech Limited · YBGJ
Yubo International Biotech Limited, headquartered in Beijing, China, specializes in the research and application of endometrial stem cells. The company also offers a diverse portfolio of products including respiratory health solutions, skincare, hair care, nutritious beverages, and personal care items, alongside specialized stem cell services under its VIVCELL brand.
Price as of Nov 19, 2026
Key Statistics
Not scored: MoonshotScore covers actively traded US operating companies, not funds, preferred shares, warrants or thinly traded stocks.
Price & valuation
| Measure | Value | As of |
|---|---|---|
| Latest provided price | $0.0055 | |
| Change on the day | 0.00% | |
| 52-week range | $0.004925 – $0.0151 | |
| Shares traded on the day | 1.0K |
Price & events
Other perspectives
Council score for Yubo International Biotech (YBGJ): perspectives
Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.
Legends Council
3 lenses, 0 current
AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built
Read on: May 26, 2026 · older than the 27 hours refresh window; not a current reading
Munger's Mindset
Balance Sheet & Valuation · historical
Read on: May 1, 2026 · older than the 27 hours refresh window; not a current reading
How to read these bars and different assessments
Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.
Bars show each model's ordered assessment on its own scale, not a probability or a comparable investment return. The adjacent words give the assessment; more filled segments indicate a stronger model reading.
On May 1, 2026, the Munger lens read the price at that time as fairly valued against its own estimate of value.
Readings on this page are from Nov 20, 2026, except a card that shows its own read date.
What is Yubo International Biotech (YBGJ), and what does it report?
Short answer · as of
A current FMP business description is unavailable; the listing and provider classification below are the available identity facts. Yubo International Biotech Limited (YBGJ) is the company analyzed here. It employs 14 people and is led by Yang Wang. In Q4 FY2025 it reported revenue of $134,391 and net income of -$136,514.
What do the latest results show for Yubo International Biotech (YBGJ)?
Short answer · as of
The most recent reported quarter, Q4 FY2025, carried revenue of $134,391.
Quarterly income statement — 1 quarters
| Period | Revenue | Net income | EPS |
|---|---|---|---|
| Q4 FY2025 | $134,391 | -$136,514 | -$0.0015 (diluted) |
What are the financial strengths and risks for Yubo International Biotech (YBGJ)?
Short answer · as of
The distress and quality screens read Altman Z -28.57 · Piotroski F 2. Trailing ratios: ROE 34.8% · current ratio 0.16 · earnings yield -90.2% · free-cash-flow yield -1.2%.
Data-derived red flags
- Financial-distress signal — its Altman Z-Score of -28.57 sits in the distress zone (elevated bankruptcy risk).
- Weak fundamentals — a Piotroski F-Score of 2/9 flags soft profitability, leverage or efficiency.
The records behind this page
Who holds the shares?
Institutional ownership reported through 13F filings.
Tracked investors
Which of the 16 named investors we follow held YBGJ in their latest 13F filing, and what they did against the filing before it.
None of the 16 tracked investors reported YBGJ in their latest 13F filing.
How to read these figures
These filings arrive after the quarter ends. Names appear as the provider lists them, not as a verified ranking, and without filing dates. Related managers can appear separately, so their shares are not added together. Tracked investors: each fund's own latest 13F, so funds that have not filed the newest quarter yet show their previous one; weight is the share of the fund's reported 13F value.
Common Questions About YBGJ
These answers are editorial: 1 of these 1 answer is drawn from the YBGJ research dossier (written Jun 15, 2026 by gemini-2.5-flash). Figures in this section are not part of the source register.
What are the key growth opportunities for YBGJ in healthcare?
YBGJ's key growth opportunities in the healthcare sector are multifaceted. A primary driver is the advancement and commercialization of its endometrial stem cell research, which could lead to novel therapeutic applications in regenerative medicine, a market projected for significant expansion.
Machine-generated analysis by Stock Expert AI — model gemini-2.5-flash, generated Jun 15, 2026. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief.
Sources: the source register lists the 12 figures on this page — 7 from Financial Modeling Prep (FMP) and 5 with no recorded source. Its rows (value as shown, as-of date, tier and source link) are in the Markdown version of this page.
Publication details and research sources
- Published
- Research standards
- Methodology · Editorial policy · Corrections
- Report a number
- sedat@stockexpertai.com